Literature DB >> 19445771

Dengue haemorrhagic fever or dengue shock syndrome in children.

Marissa M Alejandria1.   

Abstract

INTRODUCTION: Dengue haemorrhagic fever and dengue shock syndrome are major causes of hospital admission and mortality in children. Up to 5% of people with dengue haemorrhagic fever die of the infection, depending on availability of appropriate supportive care. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of supportive treatments for dengue haemorrhagic fever or dengue shock syndrome in children? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 13 systematic reviews or RCTs that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding blood component transfusion to standard intravenous fluids; adding carbazochrome sodium sulfonate, corticosteroids, or intravenous immunoglobulin to standard intravenous fluids; adding recombinant-activated factor VII to blood component transfusion; colloids; crystalloids; and intravenous fluids.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19445771      PMCID: PMC2907812     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  20 in total

Review 1.  Dengue: an update.

Authors:  María G Guzmán; Gustavo Kourí
Journal:  Lancet Infect Dis       Date:  2002-01       Impact factor: 25.071

2.  Dengue haemorrhagic fever: questions of pathogenesis.

Authors:  Mary Jane Cardosa
Journal:  Curr Opin Infect Dis       Date:  2000-10       Impact factor: 4.915

3.  Protection against marked plasma leakage in dengue haemorrhagic fever by infusion of carbazochrome sodium sulfonate (AC-17).

Authors:  Y Funahara; A Shirahata; S R Harun; R Setiabudy-Dharma; M A Nathin; T W Karjomanggolo; L A Tamaela
Journal:  Southeast Asian J Trop Med Public Health       Date:  1987-09       Impact factor: 0.267

4.  Studies on dengue hemorrhagic fever. Clinical study: an evaluation of steroids as a treatment.

Authors:  B Pongpanich; P Bhanchet; P Phanichyakarn; A Valyasevi
Journal:  J Med Assoc Thai       Date:  1973-01

5.  Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens.

Authors:  N M Dung; N P Day; D T Tam; H T Loan; H T Chau; L N Minh; T V Diet; D B Bethell; R Kneen; T T Hien; N J White; J J Farrar
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

6.  Comparison of three fluid solutions for resuscitation in dengue shock syndrome.

Authors:  Bridget A Wills; M Dung Nguyen; T Loan Ha; T H Tam Dong; T N Thuy Tran; T T Minh Le; V Diet Tran; T Hao Nguyen; V Chau Nguyen; Kasia Stepniewska; Nicholas J White; Jeremy J Farrar
Journal:  N Engl J Med       Date:  2005-09-01       Impact factor: 91.245

Review 7.  Climate change and vector-borne diseases: a regional analysis.

Authors:  A K Githeko; S W Lindsay; U E Confalonieri; J A Patz
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

8.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

Authors:  D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; T P Endy; B Raengsakulrach; A L Rothman; F A Ennis; A Nisalak
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

9.  Dengue and dengue haemorrhagic fever.

Authors:  J G Rigau-Pérez; G G Clark; D J Gubler; P Reiter; E J Sanders; A V Vorndam
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

Review 10.  Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study.

Authors:  S Tassniyom; S Vasanawathana; A Chirawatkul; S Rojanasuphot
Journal:  Pediatrics       Date:  1993-07       Impact factor: 7.124

View more
  7 in total

1.  Fatal Staphylococcal infection following classic Dengue fever.

Authors:  Stanley Almeida Araújo; Daniel Ribeiro Moreira; Juliana Marcia Ribeiro Veloso; Jenaine Oliveira Silva; Vera Lucia Souza Reis Barros; Vandack Nobre
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

2.  Intravenous immunoglobulin therapy for dengue capillary leak syndrome in a renal allograft recipient.

Authors:  Arunkumar Subbiah; Sandeep Mahajan; Raj Kanwar Yadav; Sanjay Kumar Agarwal
Journal:  BMJ Case Rep       Date:  2018-06-19

3.  Rescue therapy with intravenous immunoglobulin in severe refractory dengue: A pilot study.

Authors:  K V Padmaprakash; V K Jha; C Sowmya Karantha; Chauhan Anurag Singh; Deep Kamal; Prashant Jambunathan
Journal:  Med J Armed Forces India       Date:  2021-03-26

4.  Dengue human infection model performance parameters.

Authors:  Timothy P Endy
Journal:  J Infect Dis       Date:  2014-06-15       Impact factor: 5.226

Review 5.  Why are people with dengue dying? A scoping review of determinants for dengue mortality.

Authors:  Mabel Carabali; Libia Milena Hernandez; Maria Jose Arauz; Luis Angel Villar; Valéry Ridde
Journal:  BMC Infect Dis       Date:  2015-07-30       Impact factor: 3.090

Review 6.  Neurological Manifestations of Dengue Infection.

Authors:  Guo-Hong Li; Zhi-Jie Ning; Yi-Ming Liu; Xiao-Hong Li
Journal:  Front Cell Infect Microbiol       Date:  2017-10-25       Impact factor: 5.293

7.  Comparison of clinical and laboratory characteristics between children and adults with dengue.

Authors:  Luiz José de Souza; Laís Bastos Pessanha; Laura Carvalho Mansur; Luiza Assed de Souza; Mariana Barbosa Tâmega Ribeiro; Monique do Vale da Silveira; João Tadeu Damian Souto Filho
Journal:  Braz J Infect Dis       Date:  2013-01-11       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.